This Article Full Text (PDF) All Versions of this Article: 1403494809106544v1 37/6/647    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Semark, B. Articles by Brudin, L. Search for Related Content PubMed PubMed Citation Articles by Semark, B. Articles by Brudin, L. Social Bookmarking                         What's this?

Reimbursement for drugs — a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions

School of Human Sciences, University of Kalmar and Department of Medical Cell Biology, University of Uppsala, Sweden, birgitta.semark{at}hik.se

K. Fredlund

Primary Health Centre, Norrliden, Kalmar, Sweden

B. Åstrand

School of Pure and Applied Natural Sciences, University of Kalmar, Sweden

L. Brudin

Department of Clinical Physiology, County Hospital, Kalmar, Sweden and Department of Medicine and Health Sciences, University of Linköping, Sweden

Aims: Previous studies have indicated the negative effects of socioeconomic deprivation on health status and morbidity. Nevertheless, the economic assignment systems for pharmaceutical benefits in Sweden do not take socioeconomic status (SES) into account. The aim of the study was, therefore, to compare reimbursement for subsidized drugs at primary healthcare centres (HCCs) with differing socioeconomic conditions in relation to real costs. The word reimbursement is used to denote economic compensation to the HCCs from the county council for drug benefit costs. Methods: The numbers of individuals dispensed drugs, total costs and reimbursement at five HCCs with different socioeconomic conditions were compared. A socioeconomic index was calculated for each HCC on the basis of information from the municipality registries on income (with negative sign), assistance allowance, education, foreign background, and unemployment. Register data on drug benefit costs were retrieved from the National Corporation of Pharmacies (Apoteket AB) and the Swedish Prescribed Drug Register at the National Board of Health and Welfare. Data on listed and unlisted citizens at the Kalmar County Council and on public statistics from registers at the HCC municipalities where the HCCs were situated were retrieved. Results: There was an almost inverse linear relationship between total cost compensation and the socioeconomic index (n = 5; r =-0.99; p = 0.001). The HCCs with the lowest SES received lower cost compensation. Conclusions: HCCs responsible for citizens with lower SES appeared to be disadvantaged by the prevalent reimbursement system in Sweden, thereby increasing differences in the state of health of the citizens. This, in turn, hampers health preventing programmes and lifestyle interventions. An HCC-specific standardized summary of socioeconomic burden is presented.

Key Words: Reimbursement • primary healthcare • drug benefit • socioeconomic conditions

This version was published on August 1, 2009

Scandinavian Journal of Public Health, Vol. 37, No. 6, 647-653 (2009)
DOI: 10.1177/1403494809106544


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?